Literature DB >> 16876883

Brain nicotinic acetylcholine receptors: native subtypes and their relevance.

Cecilia Gotti1, Michele Zoli, Francesco Clementi.   

Abstract

Neuronal nicotinic acetylcholine receptors comprise a heterogeneous class of cationic channels that is present throughout the nervous system. These channels are involved both in physiological functions (including cognition, reward, motor activity and analgesia) and in pathological conditions such as Alzheimer's disease, Parkinson's disease, some forms of epilepsy, depression, autism and schizophrenia. They are also the targets of tobacco-smoking effects and addiction. Neuronal nicotinic acetylcholine receptors are pentamers of homomeric or heteromeric combinations of alpha (alpha2-alpha10) and beta (beta2-beta4) subunits, which have different pharmacological and biophysical properties and locations in the brain. The lack of subtype-specific ligands and the fact that many neuronal cells express multiple subtypes initially hampered the identification of the different native nicotinic acetylcholine receptor subtypes, but the increasing knowledge of subtype composition and roles will be of considerable interest for the development of new and clinically useful nicotinic acetylcholine receptor ligands.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16876883     DOI: 10.1016/j.tips.2006.07.004

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  338 in total

Review 1.  The role of neuromodulators in selective attention.

Authors:  Behrad Noudoost; Tirin Moore
Journal:  Trends Cogn Sci       Date:  2011-11-08       Impact factor: 20.229

2.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

3.  CHRNB2 promoter region: association with subjective effects to nicotine and gene expression differences.

Authors:  N R Hoft; J A Stitzel; K E Hutchison; M A Ehringer
Journal:  Genes Brain Behav       Date:  2010-11-04       Impact factor: 3.449

4.  Variation in the nicotinic acetylcholine receptor gene cluster CHRNA5-CHRNA3-CHRNB4 and its interaction with recent tobacco use influence cognitive flexibility.

Authors:  Huiping Zhang; Henry R Kranzler; James Poling; Joel Gelernter
Journal:  Neuropsychopharmacology       Date:  2010-07-14       Impact factor: 7.853

5.  Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors.

Authors:  Sharon R Grady; Ryan M Drenan; Scott R Breining; Daniel Yohannes; Charles R Wageman; Nikolai B Fedorov; Sheri McKinney; Paul Whiteaker; Merouane Bencherif; Henry A Lester; Michael J Marks
Journal:  Neuropharmacology       Date:  2010-01-28       Impact factor: 5.250

Review 6.  From smoking to lung cancer: the CHRNA5/A3/B4 connection.

Authors:  M R D Improgo; M D Scofield; A R Tapper; P D Gardner
Journal:  Oncogene       Date:  2010-06-28       Impact factor: 9.867

7.  Promoter IV-BDNF deficiency disturbs cholinergic gene expression of CHRNA5, CHRM2, and CHRM5: effects of drug and environmental treatments.

Authors:  Kazuko Sakata; Abigail E Overacre
Journal:  J Neurochem       Date:  2017-08-16       Impact factor: 5.372

Review 8.  Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction.

Authors:  Ruthie E Wittenberg; Shannon L Wolfman; Mariella De Biasi; John A Dani
Journal:  Neuropharmacology       Date:  2020-07-29       Impact factor: 5.250

9.  The α7 nicotinic acetylcholine receptor positive allosteric modulator attenuates lipopolysaccharide-induced activation of hippocampal IκB and CD11b gene expression in mice.

Authors:  Muzaffar Abbas; Sami Alzarea; Roger L Papke; Shafiqur Rahman
Journal:  Drug Discov Ther       Date:  2017

10.  Identifying the lipid-protein interface of the alpha4beta2 neuronal nicotinic acetylcholine receptor: hydrophobic photolabeling studies with 3-(trifluoromethyl)-3-(m-[125I]iodophenyl)diazirine.

Authors:  Ayman K Hamouda; Mitesh Sanghvi; David C Chiara; Jonathan B Cohen; Michael P Blanton
Journal:  Biochemistry       Date:  2007-11-10       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.